

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711 F: 844.513.1522

W: fresenius-kabi.ca

October 16, 2025

Acyclovir Injection, USP 500 mg per 10 mL (50 mg per mL) US-Authorized Product Allocation Notice

Dear Valued Customer.

Fresenius Kabi Canada regrets to advise that **Fresenius Kabi's US-Authorized Acyclovir Injection**, **USP 500 mg per 10 mL (50 mg per mL)** has been placed on 100% allocation effective **October 16**, **2025**. Contract customers are allocated 100% of historical Acyclovir Sodium Injection 50mg/mL, 10 mL vial demand at a 1:1 ratio, plus 100% of historical Acyclovir 50 Sodium 50 mg/mL, 20 mL vial demand at a 2:1 ratio (2 vials of US-Authorized 10 mL vial). Please see below for details

Fresenius Kabi Product Code	MSD Product Code	McKesson Product Code	Product Description	Allocation Date
622010	1000848	201602	Fresenius Kabi's US-Authorized Acyclovir Injection, USP 500 mg per 10 mL (50 mg per mL)	100% Allocation October 16, 2025 100% of 10 mL demand plus 100% of 20 mL demand at 2:1 ratio

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely.

Joseph Le

Associate Director, IV Drugs joseph.le@fresenius-kabi.com

